###begin article-title 0
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Glucocorticoid receptor gene polymorphisms associated with progression of lung disease in young patients with cystic fibrosis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 177 201 177 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glucocorticoid receptor </italic>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
The variability in the inflammatory burden of the lung in cystic fibrosis (CF) patients together with the variable effect of glucocorticoid treatment led us to hypothesize that glucocorticoid receptor (GR) gene polymorphisms may affect glucocorticoid sensitivity in CF and, consequently, may contribute to variations in the inflammatory response.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII</italic>
###xml 73 82 73 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI</italic>
###xml 257 280 257 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 257 279 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
We evaluated the association between four GR gene polymorphisms, TthIII, ER22/23EK, N363S and BclI, and disease progression in a cohort of 255 young patients with CF. Genotypes were tested for association with changes in lung function tests, infection with Pseudomonas aeruginosa and nutritional status by multivariable analysis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 240 242 240 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
A significant non-corrected for multiple tests association was found between BclI genotypes and decline in lung function measured as the forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC). Deterioration in FEV1 and FVC was more pronounced in patients with the BclI GG genotype compared to the group of patients with BclI CG and CC genotypes (p = 0.02 and p = 0.04 respectively for the entire cohort and p = 0.01 and p = 0.02 respectively for F508del homozygous patients).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
The BclI polymorphism may modulate the inflammatory burden in the CF lung and in this way influence progression of lung function.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Cystic fibrosis (CF) is an autosomal recessive disorder that is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene [1]. This gene encodes a protein that functions as a chloride channel in epithelial membranes [2]. Morbidity and mortality from CF is predominantly due to progressive loss of lung function, which follows a chronic course of inflammation, bacterial infection, and airway obstruction [3].
###end p 11
###begin p 12
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 617 640 617 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 641 654 641 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa</italic>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 617 639 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 641 654 <span type="species:ncbi:287">P. aeruginosa</span>
For a long time it was thought that the ineffective clearance of bacteria from the CF airways was primary to pathogenesis, leading secondarily to lung inflammation. However, there is now growing evidence that excessive inflammation is present very early in the airways, possibly even before infection [4]. The inflammatory response of the lung is persistently neutrophilic, with up-regulation of neutrophil chemotactic mediators such as interleukin (IL)-8 [5]. Accumulation of activated neutrophils with release of toxic products contributes to infection and subsequent chronic colonization by microorganisms such as Pseudomonas aeruginosa (P. aeruginosa) [6]. Amplification of the vicious cycle of inflammation/infection leads to progressive lung destruction.
###end p 12
###begin p 13
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1379 1381 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1602 1604 1602 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1806 1808 1806 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1809 1811 1809 1811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 1543 1551 <span type="species:ncbi:9606">patients</span>
As inflammation is a central contributor to the pathogenesis of CF pulmonary disease, limiting the excessive production of inflammatory mediators represents a major therapeutic strategy to slow the decline in lung function and to improve survival [7]. In this context, glucocorticoids are an obvious choice due to their wide range of anti-inflammatory effects, particularly on neutrophils [8]. Although beneficial, the use of systemic glucocorticoids is limited by their unacceptable side effects [9,10]. Inhaled glucocorticoids offer the possibility of increased airway deposition together with fewer systemic effects, explaining the dramatic increase in their use in CF in recent years [11]. However, the effectiveness of regular use of inhaled glucocorticoids in the management of patients with CF remains uncertain based on the results of the various trials in which inhaled glucocorticoids were compared to either placebo or standard treatment [12,13]. Indeed, no convincing conclusions could be drawn, as the reported studies were heterogeneous with respect to inclusion criteria, age, severity of pulmonary involvement, as well as type and duration of treatments. Recently, Balfour-Lynn and co-workers performed a multicenter trial to test the hypothesis that withdrawing inhaled glucocorticoids would not be associated with an earlier onset of acute chest exacerbations [14]. Their results support the conclusion from the Cochrane review that there is evidence of neither benefit nor harm, and that, most likely, specific subgroups of patients with CF may benefit from inhaled glucocorticoids [11]. Indeed, evidence indicating that significant variation among individuals to therapeutic glucocorticoids, with regard to disease response and to susceptibility to glucocorticoid side effects, exists [15,16].
###end p 13
###begin p 14
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 585 609 585 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glucocorticoid receptor </italic>
###xml 610 612 610 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR</italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 645 648 645 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S</italic>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 926 936 926 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1013 1020 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII </italic>
###xml 1128 1133 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1218 1220 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1221 1223 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1233 1234 1233 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
The clinical course in CF is highly variable, and compelling information on phenotypic variability and lack of genotype-phenotype correlation among patients with the same mutation in the CFTR gene has led to suggest that modifier genes affect the CF phenotype [17]. Recently, polymorphisms in candidate genes involved in the inflammatory cascade have been shown to modulate the expression of the clinical phenotype [18,19]. In several inflammatory diseases, variations in glucocorticoid sensitivity have been reported to be associated with single nucleotide polymorphisms (SNP) in the glucocorticoid receptor (GR) gene [16,20-22]. Among them, a GR polymorphism in exon 2 (N363S), which alters the N-terminal transactivation domain, was described to be associated with glucocorticoid hypersensitivity [20]. Another polymorphism was identified in exon 2. It comprises 2 point mutations in codons 22 and 23, and the relevant the ER22/23EK allele being linked to a decrease in the response to dexamethasone [21]. The TthIII polymorphism in the 5' untranslated region was found to be associated with basal cortisol secretion and the BclI polymorphism, located in intron 2, with an increased sensitivity to corticosteroids [22,23] (Figure 1).
###end p 14
###begin p 15
###xml 19 43 19 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glucocorticoid receptor </italic>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Positioning of the glucocorticoid receptor gene polymorphisms studied in the cystic fibrosis patients.
###end p 15
###begin p 16
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 372 375 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
The variability in the inflammatory burden of the lung in CF patients together with the variable effect of glucocorticoid treatments led us to hypothesize that GR gene polymorphisms may affect glucocorticoid sensitivity in CF and, consequently, may contribute to variations in the inflammatory response. In the present study we therefore evaluated the association between GR gene polymorphisms and disease progression in a cohort of young patients with CF.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 18
###begin p 19
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 890 893 890 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 932 937 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 1144 1145 1144 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1265 1267 1265 1267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1430 1432 1430 1432 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1652 1675 1652 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa </italic>
###xml 1676 1689 1676 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa</italic>
###xml 1885 1886 1885 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 2130 2132 2130 2132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 107 114 <span type="species:ncbi:9606">patient</span>
###xml 151 159 <span type="species:ncbi:9606">children</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 648 655 <span type="species:ncbi:9606">patient</span>
###xml 1182 1190 <span type="species:ncbi:9606">children</span>
###xml 1652 1674 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
###xml 1676 1689 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 2022 2030 <span type="species:ncbi:9606">children</span>
The study population consisted of 255 young CF patients who attended 6 French CF care centers with similar patient management (CF centers of Trousseau children hospital and Debre hospital in Paris and CF centers of Caen, Rennes, Rouen and Toulouse). The diagnosis of CF was confirmed on the basis of 2 positive sweat chloride tests (> 60 mmol/L) and identification of mutations in the CFTR gene. Over a one-year period (January to December 2005), all the patients with pancreatic insufficiency were proposed to participate in the study during their regular outpatient visits to the CF centers, and a written informed consent was obtained from each patient and/or his/her parents. The study was approved by the French ethics committee of the St. Louis Hospital (Paris). Clinical, biological and functional data were obtained retrospectively from hospital records, blinded for the results of GR genotypes. Recorded data included sex, CFTR mutations, pulmonary function tests, airway microbiology, nutritional status, impaired glucose tolerance and diabetes. Lung function was assessed by measurement of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in children > 6 yrs during periods of clinical stability. For each parameter (both FEV1 and FVC) the best value of three measurements was recorded, according to the guidelines of the European Respiratory Society and American Thoracic Society [24]. FEV1 and FVC were expressed as percentages of predicted normal values. Respiratory microbial flora was determined by microscopy and culture of lower respiratory tract secretions or throat swaps. Chronic airway infection with Pseudomonas aeruginosa (P. aeruginosa), a major cause of morbidity and mortality in CF, was defined by the persistence of the pathogen in at least three airway samples for at least 6 months. Nutritional status was appreciated by the z-score for the body mass index (BMI). Impaired glucose tolerance and diabetes were assessed by an annual oral glucose tolerance test in children > 10 yrs during periods of clinical stability according to the World Health Organisation criteria [25].
###end p 19
###begin title 20
Genotyping
###end title 20
###begin p 21
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII</italic>
###xml 114 123 114 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 203 207 203 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 387 391 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Genomic DNA was extracted from blood samples using the QIAmp DNA Blood Kit (Qiagen, Courtaboeuf, France). TthIII, ER22/23EK, N363S and BclI genotypes were obtained with the fluorogenic 5' nuclease TaqMan(R) Probe-based chemistry. First, the Polymerase Chain Reaction (PCR) in 96-well format was performed with a GeneAmp 2700 PCR system (Applied Biosystems, Foster City, USA) using TaqMan(R) probes and primers designed by Applied Biosystems.
###end p 21
###begin p 22
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII </italic>
For TthIII (rs10052957), the forward primer was 5'-GCAGAGGTGGAAATGAAGGTGAT-3', and the reverse primer was 5'-GGAGTGGGACATAAAGCTATGACAA-3'. The probe corresponding to the reference allele (labeled with fluorescent FAM) was ATTCAGACTCAGTCAAGG. The probe corresponding to the variant allele (labeled with fluorescent VIC) was TATTCAGACTCAATCAAGG.
###end p 22
###begin p 23
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
For ER22/23EK (rs6189 and rs6190), the forward primer was 5'-TCCAAAGAATCATTAACTCCTGGTAGA-3', and the reverse primer was 5'-GCTCCTCCTCTTAGGGTTTTATAGAAG-3'. The probe corresponding to the reference allele (labeled with fluorescent VIC) was ATCTCCCCTCTCCTGAG. The probe corresponding to the variant allele (labeled with fluorescent FAM) was ATCTCCCTTTTCCTGAGCA.
###end p 23
###begin p 24
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
For N363S (rs6195), the primer sequences were not supplied by Applied Biosystem. The probe corresponding to the reference allele (labeled with fluorescent FAM) was TCCAGATCCTTGGCACCTATTCCAATTTTCGGAACCAACGGGAATT. The probe corresponding to the variant allele (labeled with fluorescent VIC) was TCCACATCCTTGGCACCTATTCCAACTTTCGGAACCAACGGGAATT.
###end p 24
###begin p 25
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
For BclI (rs not available), the forward primer was 5'-CAGGGTTCTTGCCATAAAGTAGACA-3', and the reverse primer was 5'-GCACCATGTTGACACCAATTCC-3'. The probe corresponding to the reference allele (labeled with fluorescent FAM) was CTCTTAAAGAGATTCATCAGC. The probe corresponding to the variant allele (labeled with fluorescent VIC) was CTCTTAAAGAGATTGATCAGC.
###end p 25
###begin p 26
The PCR conditions and cycling followed the manufacturer's instructions. Allelic discrimination was performed by endpoint measurements on the 7500 Real Time PCR System (Applied Biosystems). Genotyping data were collected for statistical analysis.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 322 332 320 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
###xml 336 341 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S</italic>
###xml 634 636 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 637 639 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 627 632 <span type="species:ncbi:9606">child</span>
Statistical analyses were performed for the entire cohort and in the subgroup of patients F508del homozygous. Data were expressed as a percentage, mean (+/- SD) or median [interquartile range]. Conformance of the allele frequencies with the Hardy-Weinberg equilibrium was tested using a using Fisher's exact test. For SNP ER22/23EK and N363S, the least frequent homozygous type was grouped with the heterozygous type for the statistical analyses. SNP pairwise linkage disequilibrium was evaluated by Lewontin's D'. Haplotypes were reconstructed with the EM algorithm and only the most probable resolution was retained for each child [26,27]. Haplotypes with frequencies <1% were grouped with the most frequent haplotype.
###end p 28
###begin p 29
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 58 72 58 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 453 458 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 58 71 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 228 235 <span type="species:ncbi:9606">patient</span>
The association between the GR genotype and time to first P. aeruginosa infection was evaluated with proportional hazards regression models. Univariable and multivariable analyses were performed. Associations with the following patient characteristics were tested with the log likelihood ratio test: gender, circumstances of CF diagnosis (neonatal screening, meconium ileus, later diagnosis on clinical symptoms), birth date (cohort effect), CF centre, CFTR genotype, and pancreatic status.
###end p 29
###begin p 30
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 334 335 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Longitudinal linear mixed effect models were applied to FEV1, FVC and BMI z-score data to determine the patterns of change in pulmonary function and nutritional status with age and genotype. The mixed effect model takes into account the correlation within observations measured for the same subject. On the regression line linking FEV1, FVC or BMI to age, both the intercept (at 5 years) and slope could depend on the genotype, or on the count of haplotypes. Measurements between age 6 and 16 were used in the analyses. All models were adjusted at maximum likelihood, and the influence of genotype was tested by the Wald test. A single step permutation based correction for multiple SNP testing was made as described by Westfall and Young [28]. For each of 5000 surrogate datasets obtained by permuting individual genotypes, mixed model analysis was applied to the 4 SNP and the minimum P-value was recorded. The corrected P-value corresponds to the probability of finding a smaller P-value in the permutations.
###end p 30
###begin p 31
###xml 40 42 40 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Statistical significance was defined as P < 0.05. Statistical analyses were carried out with the R software (v2.4.0).
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient clinical characteristics
###end title 33
###begin p 34
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 218 226 214 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F508del </italic>
###xml 244 252 240 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F508del </italic>
###xml 291 296 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 330 335 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G542X</italic>
###xml 337 342 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G551D</italic>
###xml 344 351 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I507del</italic>
###xml 353 360 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N1303K </italic>
###xml 364 373 360 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1717-1G&gt;A</italic>
###xml 427 440 423 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa</italic>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 427 440 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of the study population are listed in Table 1. The mean age at enrollment was 11.1 +/- 5.1 years and the mean duration of follow-up was 11.2 +/- 6.0 years. 136 out of the 255 patients were F508del homozygous and 91 F508del compound heterozygous. Among the other CFTR mutations, the most frequent were G542X, G551D, I507del, N1303K and 1717-1G>A. 60% of the patients were chronically colonized with P. aeruginosa. As the average age of onset of diabetes in CF is 18-21 years, the number of patients with impaired and diabetic glucose tolerance in this paediatric cohort was relatively low; 21 with impaired glucose tolerance and 15 with diabetes.
###end p 34
###begin p 35
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of cystic fibrosis patients
###end p 35
###begin p 36
###xml 27 40 27 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa</italic>
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa</italic>
###xml 27 40 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 42 64 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
Abbreviations: yrs: years; P. aeruginosa: Pseudomonas aeruginosa
###end p 36
###begin p 37
* Cumulated incidence by Kaplan-Meier estimate
###end p 37
###begin title 38
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
Allele frequencies of GR polymorphisms
###end title 38
###begin p 39
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
The genotype distributions in the studied patients are listed in Table 2. All the 255 patients have been genotyped for the 4 polymorphisms studied. The frequencies of the tested alleles and genotypes were similar to reported frequencies in control populations [20,22,29,30]. The population did not deviate significantly from the Hardy-Weinberg equilibrium indicating no bias in sampling in the examined population or problems with genotyping of the collected samples, and reflecting a random allele distribution.
###end p 39
###begin p 40
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Genotype frequencies and p-value for Hardy-Weinberg equilibrium (HWE) in the cystic fibrosis patients. The genotype frequencies from previous studies in Caucasians are listed for comparison.
###end p 40
###begin title 41
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
Analysis of changes in respiratory parameters with GR genotypes
###end title 41
###begin p 42
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 234 236 232 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 303 305 297 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 318 321 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 517 518 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 626 628 620 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 690 695 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 789 794 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1041 1043 1029 1031 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1064 1069 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1107 1112 1095 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1230 1235 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1259 1264 1247 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1571 1572 1559 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
###xml 987 995 <span type="species:ncbi:9606">patients</span>
###xml 1046 1054 <span type="species:ncbi:9606">patients</span>
###xml 1093 1101 <span type="species:ncbi:9606">patients</span>
###xml 1208 1216 <span type="species:ncbi:9606">patients</span>
###xml 1335 1343 <span type="species:ncbi:9606">patients</span>
###xml 1519 1527 <span type="species:ncbi:9606">patients</span>
Changes in lung function (FEV1 and FVC) were examined for each genetic locus. The decline in FEV1 and FVC was analyzed by linear mixed model regression. This model predicts for the entire cohort a mean (+/- SD) decline per year in FEV1 of 2.3 (+/- 0.3)%, and in FVC of 1.7 (+/- 0.3)%. The decline in FEV1 and FVC with GR genotype as covariate was analyzed in the total population and in the subpopulation of F508del homozygous patients. The estimated values at 6-year and slopes in change per year are shown in Table 3 for the entire cohort and for the homogeneous subgroup of F508del homozygous patients. Deterioration in FEV1 in the entire cohort was more pronounced in patients with the BclI GG genotype (annual slope of decline, k: -3.4 +/- 0.5) compared to the group of patients with BclI CG and CC genotypes (annual slopes of decline, k: -2.8 +/- 0.7 and -2.3 +/- 0.5 respectively, p = 0.02). This association was also significant in the homogeneous subgroup of F508del homozygous patients with a more pronounced rate of decline in FEV1 in patients with the BclI GG genotype compared to patients with BclI CG and CC genotypes (p = 0.01). Similarly, analysis of FVC data showed a more severe decline in patients carrying the BclI GG genotype compared to BclI CG and CC genotypes in the entire cohort and in the F508del homozygous patients (p = 0.04 and p = 0.02 respectively). After correction for multiple testing, these associations were borderline significant in the entire cohort and in the F508del homozygous patients (p = 0.07 and p = 0.06 respectively for FEV1).
###end p 42
###begin p 43
###xml 12 36 12 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glucocorticoid receptor </italic>
###xml 77 79 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Analysis of glucocorticoid receptor genotypes and longitudinal trends for FEV1 and FVC
###end p 43
###begin p 44
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 100 102 100 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Abbreviations: Y: years; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity. FEV1 and FVC are expressed as percentages of predicted values.
###end p 44
###begin p 45
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 220 224 216 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">age </sub>
###xml 227 229 223 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 231 233 227 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k </italic>
Statistical analysis: Mixed model regression for FEV1, FVC according to age. Results are expressed as estimated value at 6 years (Y6 +/- SD) and average decline per year (k +/- SD). Mixed model equation is expressed as Yage = Y6 - k (age - 6). *p < 0.05.
###end p 45
###begin p 46
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ThIII</italic>
###xml 15 25 15 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
For the ThIII, ER22/23EK and N363S variants, analysis of FEV1 or FVC data revealed no significant difference between the different genotypes.
###end p 46
###begin p 47
###xml 100 114 100 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ThIII</italic>
###xml 173 182 173 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 100 113 <span type="species:ncbi:287">P. aeruginosa</span>
In a Cox regression model, we did not find any significant association between the age of the first P. aeruginosa infection or acquisition of colonization and either ThIII, ER22/23EK, N363S or BclI variants (data not shown).
###end p 47
###begin title 48
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
Analysis of changes in respiratory parameters with GR haplotypes
###end title 48
###begin p 49
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII</italic>
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI</italic>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
Linkage disequilibrium between pairs of GR alleles (TthIII, ER22/23EK, N363S and BclI) was analyzed using D' coefficient (Lewontin's standardized disequilibrium coefficient). The D' values for the pairs were indicative of linkage disequilibrium (D' values between 0.17 to 0.99, and p values between 0.05 to <0.0001), leading to extend the study to haplotypes across the GR gene.
###end p 49
###begin p 50
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII</italic>
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 257 266 257 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII/C </italic>
###xml 268 280 268 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK/G </italic>
###xml 282 290 282 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S/A </italic>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI/C</italic>
###xml 349 352 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 382 384 382 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The reconstructed haplotype frequencies for TthIII, ER22/23EK, N363S and BclI were calculated. We found that the 4 single-nucleotide polymorphisms were segregated as 6 distinct haplotypes, with frequencies listed in Table 4. The most frequent haplotype was TthIII/C - ER22/23EK/G - N363S/A - BclI/C. Haplotype trend regression was used to associate GR haplotypes with changes in FEV1 and FVC but no significant association could be documented.
###end p 50
###begin p 51
###xml 29 53 29 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">glucocorticoid receptor </italic>
Haplotype frequencies in the glucocorticoid receptor gene
###end p 51
###begin title 52
Influence of the GR genotype on nutritional parameters
###end title 52
###begin p 53
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 182 187 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 220 225 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
The decline in the BMI z-score, from 6 to 16 years was analyzed by mixed model regression. For BclI genotypes, the annual rates of decline in the BMI z-score were -0.04 +/- 0.02 for BclI CC and CG and -0.05 +/- 0.04 for BclI GG (p = 0.7).
###end p 53
###begin p 54
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ThIII</italic>
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
No significant association was found between either ThIII, ER22/23EK, N363S or BclI variants and the nutritional parameters tested, which included decline in the BMI z-score, impaired glucose tolerance and diabetes.
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 70 73 70 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 319 322 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 368 371 368 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
A novel finding of the present study is that BclI polymorphism in the GR gene seems to be associated with lung disease progression in CF. Indeed, analysis of pulmonary function data showed a more pronounced rate in decline in patients carrying the BclI GG genotype. These observations are consistent with the effect of GR polymorphism on gene products and the role of GR in the control of the inflammatory response of the lung in CF.
###end p 56
###begin p 57
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR </italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
###xml 646 653 <span type="species:ncbi:9606">patient</span>
Despite the monogenic nature of CF, the clinical course in this disease is highly variable in patients with identical CFTR genotypes [17]. Although environmental factors may contribute to this variation, several host genetic factors that code outside of CFTR locus have been reported to modulate the expression of several clinical phenotypes. Identification of modifier genes that may influence disease progression is becoming an important challenge in CF not only to progress in the understanding of CF pathophysiology but also to identify the patients who may benefit from new therapeutic strategies and to adapt the treatment according to the patient's genetic profile. Among the candidate genes of interest are the genes that can interfere with the inflammatory cascade and the response to anti-inflammatory agents [18,19].
###end p 57
###begin p 58
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 526 528 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1089 1091 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1150 1153 1146 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
Genes that influence the exogenous as well as endogenous glucocorticoid effects have been examined as potential modifiers in the present study. The key contributor to glucocorticoid action is GR, a member of the steroid-hormone-receptor family of proteins. Within the cell, the cortisol-GR complex can bind as a homodimer to the glucocorticoid-response elements and enhance or represses transcription of specific target genes [31]. The complex can also interact with other transcription factors such as nuclear factor-kappaB [32]. Other modes of action include glucocorticoid signaling through membrane associated-receptors. Therefore, it is currently believed that GR could inhibit inflammation through various genomic and non-genomic mechanisms. To date only one gene has been identified for GR, but several GR isoforms are generated by alternate splicing, alternative translation initiation, and each isoform is subject to a variety of post-translational modifications which play an important role in the subcellular distribution, protein turnover and transcriptional activities of GR [33]. In addition to the complexity of the multiple isoforms, GR mutations and polymorphisms may also affect protein expression, structure and function, and thus may have diverse clinical consequences.
###end p 58
###begin p 59
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S</italic>
###xml 127 136 127 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK</italic>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII </italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N363S </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">363S </italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 402 412 402 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
###xml 529 539 529 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER22/23EK </italic>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 759 766 759 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TthIII </italic>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1221 1226 1221 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1266 1269 1266 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 1366 1369 1366 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 855 858 <span type="species:ncbi:9606">men</span>
Several SNP in the GR gene have been reported to be associated with variation in glucocorticoid sensitivity, mainly the N363S, ER22/23EK, TthIII and the BclI polymorphisms [20,22,29,30]. The N363S polymorphism is a non synonymous SNP and the 363S allele has been associated with a higher BMI, enhanced cortisol suppression and an increased insulin response after dexamethasone administration [20]. The ER22/23EK polymorphism consists of two linked point mutations, the first is synonymous while the second is non synonymous. The ER22/23EK variant allele has been reported to be associated with a greater sensitivity to insulin, lower total and low-density lipoprotein cholesterol levels, and a beneficial body composition at a young adult age [21,29,34]. The TthIII polymorphism has been shown to be associated with changes in basal cortisol secretion in men [23]. The BclI polymorphism previously characterized as the large (4.5 kb) and small (2.3 kb) restriction fragments has recently been identified as a C to G mutation in intron 2, 646 bp downstream from exon 2 [22]. Several investigations have found association between the large allele or the GG genotype and parameters indicative of insulin resistance. As this BclI polymorphism is intronic, its effect on GR gene activity may be indirect. It is currently suggested that this polymorphism might affect the GR gene promoter by selectively acting either on repressor or enhancer sites.
###end p 59
###begin p 60
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 605 608 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1133 1138 1133 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 1278 1286 1278 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1441 1444 1441 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 1662 1667 1662 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 2216 2221 2216 2221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 2336 2341 2336 2341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 2547 2552 2547 2552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 2726 2728 2726 2728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2891 2894 2891 2894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl</italic>
###xml 2949 2954 2949 2954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 2999 3001 2999 3001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 3048 3053 3048 3053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 3150 3152 3150 3152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 994 999 <span type="species:ncbi:9606">human</span>
###xml 1640 1648 <span type="species:ncbi:9606">patients</span>
###xml 2792 2795 <span type="species:ncbi:9606">men</span>
The mechanisms by which the BclI polymorphisms could influence lung function and lung disease progression in CF remain to be elucidated. One explanation may be drawn from the results of several studies showing that this polymorphism influences glucocorticoid sensitivity [22,35-37]. In a number of chronic inflammatory disorders, evidence of decreased glucocorticoid sensitivity of blood cells has been reported [38-40]. The cause of this reduction remains at present unknown, but might, at least, in part, be genetically determined. As indicated above, the BclI polymorphism could affect differently the GR promoter leading to differences in receptor expression levels. By interacting with either repressor or enhancer sites within the promoter, glucocorticoid sensitivity would be increased or decreased. Differential usage of the promoter is likely to contribute to a variable response in a tissue-specific manner. This is supported by the data provided by Panarelli and coworkers in normal human subjects [37]. These authors showed that the skin sensitivity to budesonide was enhanced in subjects carrying the GG variants of the BclI polymorphisms compared with the CC subjects. In contrast, white blood cells of the GG subjects tended to be less sensitive to dexamethasone in vitro. Although these findings were not statistically significant, the authors suggested that this polymorphism might have tissue-specific effects and that the GR genotype could affect steroid sensitivity in a tissue-specific manner. As the inflammatory process in CF is dominated by a neutrophil influx in the airways, our present findings reporting that CF patients carrying the BclI GG genotype showed a more severe decline in lung function may be consistent with the findings of Panarelli and coworkers with a decrease in glucocorticoid sensitivity and, consequently, a higher inflammatory burden. As a result, the increased intensity of the inflammatory reaction may also contribute to glucocorticoid resistance as cytokines have been reported to influence glucocorticoid sensitivity in various tissues. However, this proposed mechanism does not rule out the possibility that other genetic variants in linkage disequilibrium with BclI polymorphism are of functional importance. As suggested by several studies, the effects found in our study for the BclI polymorphism could also represent a combination of endogenous effects, hypothalamic-pituitary-adrenal (HPA) axis, and exogenous effects, glucocorticoid treatment. van Rossum and coworkers demonstrated that BclI G-allele carriers had lower cortisol levels after dexamethasone treatment, suggesting that they are more sensitive to the feedback action of glucocorticoids on the HPA axis [22]. In addition, Rosmond and coworkers in a study of 284 Swedish men, have shown that stimulated cortisol secretion after a standardized lunch differed between the BclI genotypes, which suggests an association between the BclI polymorphism and regulation of the HPA axis [23]. A glucocorticoid receptor polymorphism like BclI described to be associated with less immune suppression might be interesting for future studies [41].
###end p 60
###begin p 61
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
In the present study, we did not find association of the other studied GR polymorphisms with lung disease progression evaluated from the slopes of decline in lung function parameters. Neither did we observe association of any of the studied polymorphisms with nutritional status and glucose metabolism. Several reasons can be put forward to explain these results. They include the types and the sensitivity of the phenotypic parameters analyzed, the role of the studied polymorphisms, and the potential contribution of the studied variants with rather low allele frequencies, which may exert only moderate effects. In addition, our studied population included only young patients. Several recent reports on the possible influence of modifier genes in CF provided evidence that there are disease stage-specific effects and that these effects are certainly more difficult to detect in young patients [42].
###end p 61
###begin p 62
###xml 64 67 64 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GR </italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 648 650 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 817 819 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
The present report is the first investigating the impact of the GR polymorphisms on expression of lung disease in CF. So far, studies performed on chronic respiratory disorders have mainly focused on asthma [16]. Steroid-resistant asthmatics have a disease that fails to respond to high-dose steroid therapy, despite the fact that the obstruction of their airways is reversible in response to inhaled beta-2 agonists. Several investigators have provided data suggesting increased expression of GRbeta, a splice variant of the GRalpha isoform that does not bind glucocorticoid ligands and is unable to transactivate glucocorticoid responsive genes [43]. In interstitial lung diseases, it is suggested that the different responses to glucocorticoids may also be the results of differences in the expression of GRalpha [44].
###end p 62
###begin p 63
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
Although the results of our study require further confirmation, the findings may have important therapeutic implications. The association of BclI polymorphism and lung disease progression in CF gives support to the concept that specific subgroups of patients with CF may benefit from the use of glucocorticoids preferably by the inhaled route. If true, this should allow discriminatory prescribing which is of tremendous importance for several reasons. One is the constant increase in the use of inhaled glucocorticoids in patients with CF. However, as indicated above, there is little evidence to justify their routine and widespread use [14]. Although there is currently compelling results to consider anti-inflammatory molecules as a major therapeutic strategy for slowing the decline in lung function and improving survival, inhaled glucocorticoids should be selectively prescribed to patients who may benefit from them [7]. However, assessment of the effect of these molecules is difficult in CF. Consequently, inhaled glucocorticoids are often maintained at high doses for long periods despite the increasing recognition that they can lead to significant adverse effects such as adrenal suppression.
###end p 63
###begin p 64
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 15 22 <span type="species:ncbi:9606">patient</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
In addition to patient age, a number of limitations of our study should be raised. First, the size of the population. Although, we have studied a high enough sample size for detection of significant differences, replication in additional cohorts is required to validate the association of BclI polymorphisms and lung disease progression in CF. In addition, the implication of the other GR polymorphisms should be tested in larger groups of patients. Another concern relates to the retrospective collection of the data from patients' medical records, leading our study shearing the general limitations of retrospective studies. Information was collected from physicians in charge of the patients as the primary source of data. All the treatments the patients received were recorded. However, data on the use of inhaled glucocorticoids could not be adequately obtained due to the large variation in molecules, drug dosages, regimens, and duration of treatment given to the patients. In addition, the adherence of each individual to the prescribed inhaled glucocorticoids could not be ascertained.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BclI </italic>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
In conclusion, we report for the first time the possible association between BclI polymorphism of the GR gene and the progression of lung disease in CF. Identification of factors implicated in the glucocorticoid response has important implications in predicting the individual therapeutic outcome. This pharmacogenetic approach should help to optimize anti-inflammatory therapy in patients with CF.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
None of the authors have any commercial or other associations that might pose a conflict of interest. All of the authors are aware and agree to the content of the paper and approve its submission.
###end p 68
###begin title 69
Authors' contributions
###end title 69
###begin p 70
###xml 303 311 <span type="species:ncbi:9606">patients</span>
HC, drafting the manuscript, and NN have been involved in conception and design of the study and in acquisition and interpretation of data. CC has been involved in the acquisition of the data. KC, PLR and OT have been involved in the interpretation of the data. AH-C has been involved in collecting the patients DNA and the phenotypical data. BF and JF have been involved in revisiting the manuscript. P-YB has performed all the statistical analyses. AC has been involved in conception and design of the study and in critically revisiting the manuscript.
###end p 70
###begin title 71
Financial support
###end title 71
###begin p 72
Institut National de la Sante et de la Recherche Medicale, Assistance Publique-Hopitaux de Paris, Universite Pierre et Marie Curie Paris, Agence Nationale de la Recherche, Association Vaincre La Mucoviscidose, Chancellerie des Universites (Legs Poix), Association Agir Informer Contre la Mucoviscidose, GIS-Institut des Maladies Rares.
###end p 72
###begin title 73
Acknowledgements
###end title 73
###begin p 74
###xml 188 196 <span type="species:ncbi:9606">patients</span>
The authors thank Pr Jacques Brouard Dr. Francois Bremont, Dr. Bertrand Delaisi, Pr. Jean-Francois Duhamel, Pr. Christophe Marguet, and Pr. Michel Roussey for allowing them to study their patients, and for their comments. They wish to acknowledge Marie-Claude Miesch for her technical assistance and Cyril Flamant for his assistance in collecting the phenotypical data.
###end p 74
###begin article-title 75
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA
###end article-title 75
###begin article-title 76
New concepts of the pathogenesis of cystic fibrosis lung disease
###end article-title 76
###begin article-title 77
Cystic fibrosis since 1938
###end article-title 77
###begin article-title 78
New insights into pulmonary inflammation in cystic fibrosis
###end article-title 78
###begin article-title 79
###xml 64 72 <span type="species:ncbi:9606">children</span>
Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis
###end article-title 79
###begin article-title 80
###xml 38 46 <span type="species:ncbi:9606">patients</span>
State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?
###end article-title 80
###begin article-title 81
Lung inflammation as a therapeutic target in cystic fibrosis
###end article-title 81
###begin article-title 82
###xml 59 67 <span type="species:ncbi:9606">patients</span>
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group
###end article-title 82
###begin article-title 83
Oral steroids for cystic fibrosis
###end article-title 83
###begin article-title 84
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Risks of alternate-day prednisone in patients with cystic fibrosis
###end article-title 84
###begin article-title 85
Inhaled corticosteroids for cystic fibrosis
###end article-title 85
###begin article-title 86
Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis
###end article-title 86
###begin article-title 87
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection
###end article-title 87
###begin article-title 88
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis
###end article-title 88
###begin article-title 89
Heterogeneity of therapeutic responses in asthma
###end article-title 89
###begin article-title 90
Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype
###end article-title 90
###begin article-title 91
Modifier genetics: cystic fibrosis
###end article-title 91
###begin article-title 92
Genetic modifiers of lung disease in cystic fibrosis
###end article-title 92
###begin article-title 93
Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype
###end article-title 93
###begin article-title 94
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo
###end article-title 94
###begin article-title 95
A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels
###end article-title 95
###begin article-title 96
Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index
###end article-title 96
###begin article-title 97
###xml 130 133 <span type="species:ncbi:9606">men</span>
A polymorphism of the 5'-flanking region of the glucocorticoid receptor gene locus is associated with basal cortisol secretion in men
###end article-title 97
###begin article-title 98
Sources of variation in FEV1
###end article-title 98
###begin article-title 99
Diabetes mellitus. Report of a WHO Study Group
###end article-title 99
###begin article-title 100
The Interaction of Selection and Linkage. Ii. Optimum Models
###end article-title 100
###begin article-title 101
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population
###end article-title 101
###begin article-title 102
Resampling-based multiple testing: examples and methods for P-value adjustment
###end article-title 102
###begin article-title 103
The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults
###end article-title 103
###begin article-title 104
Characterization of a promoter polymorphism in the glucocorticoid receptor gene and its relationship to three other polymorphisms
###end article-title 104
###begin article-title 105
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs
###end article-title 105
###begin article-title 106
Corticosteroid effects on cell signalling
###end article-title 106
###begin article-title 107
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human glucocorticoid receptor: one gene, multiple proteins and diverse responses
###end article-title 107
###begin article-title 108
###xml 133 136 <span type="species:ncbi:9606">men</span>
Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men
###end article-title 108
###begin article-title 109
###xml 136 144 <span type="species:ncbi:9606">patients</span>
The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients
###end article-title 109
###begin article-title 110
Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition
###end article-title 110
###begin article-title 111
###xml 115 120 <span type="species:ncbi:9606">human</span>
Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects
###end article-title 111
###begin article-title 112
Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents
###end article-title 112
###begin article-title 113
###xml 122 130 <span type="species:ncbi:9606">patients</span>
The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma
###end article-title 113
###begin article-title 114
Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes
###end article-title 114
###begin article-title 115
Glucocorticoid receptor polymorphism affects transrepression but not transactivation
###end article-title 115
###begin article-title 116
Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles
###end article-title 116
###begin article-title 117
Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma
###end article-title 117
###begin article-title 118
Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases
###end article-title 118
###begin article-title 119
A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis
###end article-title 119

